MedTech Terms
    The authoritative reference
    All terms
    Investment & FinanceStartup Lifecycle

    Protective Provisions

    Veto rights held by preferred stockholders (usually voting as a class) over specified corporate actions, negotiated in the certificate of incorporation.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed September 19, 2026

    Definition

    Protective provisions are contractual or charter-based veto rights that require the affirmative consent of a specified percentage (often a majority) of one or more series of preferred stock, voting separately as a class or together as a single class, before the company can take certain actions. Typical protected actions include amending the certificate of incorporation, authorizing a new senior or pari passu class of stock, incurring debt above a threshold, changing the size of the board, selling or licensing substantially all assets, and effecting a merger, acquisition, or dissolution. Protective provisions are set out in the certificate of incorporation (making them enforceable against all future stockholders, not just signatories to a contract) and are a standard element of the NVCA model documents.
    What the regulation says
    Protective provisions are corporate governance rights, not MedTech product regulations. For Delaware corporations, the Delaware General Corporation Law (DGCL), 8 Del. C. § 151, permits preferred stock rights to be specified in the certificate of incorporation. Section 242 governs charter amendments, generally requiring board approval and applicable stockholder approval, subject to statutory exceptions. Section 242(b)(2) also provides separate class voting rights for certain amendments, including those adversely changing a class's powers, preferences, or special rights. These statutory protections are distinct from negotiated veto rights. The charter determines which additional actions require preferred stockholder consent and the applicable voting threshold. Contractual protections also have statutory support. Delaware Senate Bill 313, effective August 1, 2024, added DGCL § 122(18), expressly authorizing certain stockholder agreements that require consent before specified corporate actions, subject to statutory limits. Contractual consent rights should not be treated as interchangeable with charter provisions, particularly regarding who is bound. The National Venture Capital Association's Model Certificate of Incorporation provides a drafting framework for preferred stock protective provisions, but it is not legislation or a mandatory regulatory standard. For a MedTech company, these provisions may affect financing, acquisitions, and significant intellectual property transactions; their scope depends on the adopted documents.

    What this means in practice

    For MedTech companies, protective provisions frequently give investors control over decisions that affect the regulatory and clinical strategy indirectly, such as approving budgets for a pivotal trial, taking on venture debt to bridge to a milestone, or accepting a licensing deal with a strategic partner before a full acquisition. Founders should track exactly which actions require a preferred class vote versus only board approval, since a single blocking investor series can stall a time-sensitive transaction.

    Examples

    • A certificate of incorporation requires the consent of holders of a majority of outstanding Series A and Series B preferred, voting together as a single class, before the company can raise a new financing round senior to Series B. If the company wants to raise emergency bridge financing on senior terms after a delayed FDA decision, it must obtain that majority consent even if the board otherwise approves the raise.
    • A company negotiates its Series C term sheet with a $10,000,000 debt-incurrence threshold requiring preferred consent above that amount. When the company later needs an $8,000,000 equipment financing facility to build commercial-scale manufacturing ahead of launch, it does not need preferred consent because the amount is below the threshold; a subsequent $6,000,000 working-capital loan would push cumulative debt above $10,000,000 and would require consent.
    Common pitfalls
    • •Assuming board approval is sufficient for actions that also require a separate preferred class vote under protective provisions; closing a financing or sale without that consent can be void or subject to rescission.
    • •Not tracking how protective provisions stack across multiple preferred series after several financing rounds, since later series often negotiate broader veto rights than earlier ones.
    • •Overlooking that protective provisions typically survive and can complicate a down round or restructuring, since the very investors whose price is being reduced may need to consent to the transaction that reduces it.

    Frequently asked questions

    No. Protective provisions are stockholder-level veto rights exercised by preferred stockholders voting as a class under the charter, separate from any consent rights a specific investor's board designee might have at the board level.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 2Tier 4Trade press and expert commentary· 1
    Link health: 1 verified 2 unchecked· last checked 2026-06-20
    NVCA·1Delaware General Assembly·1Cornell Law LII·1
    1. 1
      NVCA Model Certificate of Incorporation
      Tier 4 Verified
      NVCAnvca.org
    2. 2
      Delaware Code Title 8, Section 242
      Tier 1 Unchecked
      Delaware General Assemblydelcode.delaware.gov
    3. 3
      Cornell LII: Preferred Stock
      Tier 1 Unchecked
      Cornell Law LIIlaw.cornell.edu

    Inline markers like [1] jump to the matching reference above.